FBB
MRNA icon

Fulton Breakefield Broenniman’s Moderna MRNA Stock Holding History

Fulton Breakefield Broenniman’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,810
Closed -$215K – 189
2024
Q2 		$215K Buy
+1,810
New +$229K 0.02% 176
2023
Q3 		– Sell
-1,755
Closed -$213K – 170
2023
Q2 		$213K Sell
1,755
-4
-0.2% -$534 0.02% 168
2023
Q1 		$270K Buy
1,759
+4
+0.2% +$660 0.02% 146
2022
Q4 		$315K Hold
1,755
– – 0.03% 143
2022
Q3 		$208K Hold
1,755
– – 0.02% 156
2022
Q2 		$251K Sell
1,755
-50
-3% -$7.15K 0.02% 152
2022
Q1 		$311K Hold
1,805
– – 0.03% 135
2021
Q4 		$458K Sell
1,805
-150
-8% -$43.9K 0.03% 137
2021
Q3 		$752K Buy
1,955
+45
+2% +$16.6K 0.06% 92
2021
Q2 		$449K Hold
1,910
– – 0.04% 134
2021
Q1 		$250K Hold
1,910
– – 0.02% 161
2020
Q4 		$200K Buy
+1,910
New +$193K 0.02% 134

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fulton Breakefield Broenniman's MRNA Position: Q3 2024 in Review

Fulton Breakefield Broenniman sold out of Moderna (MRNA) in Q3 2024, closing a stake of 1,810 shares — an estimated $215K sold.

Fulton Breakefield Broenniman first reported a position in MRNA in Q4 2020 and held it in 12 quarters. The position peaked at $752K in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Fulton Breakefield Broenniman reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Fulton Breakefield Broenniman sold 1,810 Moderna shares in Q3 2024, an estimated $215K.
  • Fulton Breakefield Broenniman first reported a position in Moderna in Q4 2020 and held it in 12 quarters.
  • Fulton Breakefield Broenniman's Moderna position peaked at $752K in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Fulton Breakefield Broenniman's 13F filing for Q3 2024, filed 16 Oct 2024.